Article
Oncology
Kazuma Kobayshi, Koichi Suyama, Hiroo Katsuya, Naoki Izawa, Yoshikazu Uenosono, Qingjiang Hu, Tetsuya Kusumoto, Hajime Otsu, Hiroyuki Orita, Hirofumi Kawanaka, Kazunori Shibao, Satoshi Koga, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Eiji Oki, Hideo Baba, Masaki Mori
Summary: The KSCC1701 study evaluated the efficacy and safety of S1 + ramucirumab in elderly patients with ARGC. The 1-year OS rate was 65.2%, with a median survival time of 16.4 months and an ORR of 41.9%. This treatment option appears to be excellent for elderly patients with ARGC.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Biotechnology & Applied Microbiology
Dengfeng Ren, Guoxiu Wang, Yu Zhang, Jie Kan, Qiuxia Dong, Junhui Zhao, Faxiang Ji, Hao Li, Yushuang Luo, Mingzhe Lin, Guoyuan Li, Zhibo Liu, Xinfu Ma, Qijing Guo, Fuxing Zhao, Guoshuang Shen, Jiuda Zhao
Summary: The study suggests that apatinib is effective and relatively tolerable for elderly patients with unresectable advanced or metastatic gastric cancer who have received at least first-line chemotherapy.
ONCOTARGETS AND THERAPY
(2021)
Article
Medicine, Research & Experimental
Xiaoting Ma, Yujian Zhang, Cong Wang, Jing Yu
Summary: The study evaluated the efficacy and safety of taxanes combined with basic chemotherapy in the first-line treatment of advanced gastric cancer. The results showed that compared to chemotherapy without taxanes, taxanes combined with basic chemotherapy significantly improved progression-free survival and overall survival in patients, as well as achieving better objective response rate and disease control rate. However, this treatment also increased the incidence of certain side effects.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Fortunato Ciardiello, Yung-Jue Bang, Andres Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean-Philippe Metges, Antonio Sanchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Zhaoyin Zhu, Neal Gupta, Robert J. Pelham, Lin Shen
Summary: The study investigated the efficacy and safety of maintenance therapy with Pamiparib in gastric cancer. The results showed that Pamiparib did not demonstrate a significant superiority in progression-free survival (PFS) compared to placebo, but it was well tolerated with few adverse events.
Article
Oncology
Xuetong Rong, Haiyi Liu, Hongmei Yu, Jian Zhao, Jie Wang, Yusheng Wang
Summary: This study evaluated the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer. It found that baseline neutrophil and alkaline phosphatase levels were independent prognostic factors. The treatment regimen showed good efficacy and safety.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Immunology
Xiaoying Qian, Yong Wang, Fanrong Liu, Yong Yuan, Chen Fang, Xinwei Zhang, Shangkun Yuan, Renfang Chen, Biao Yu, Tong Wang, Yan Yin, Yong Li
Summary: This study retrospectively analyzed the efficacy of first-line immune checkpoint inhibitors (ICIs) in 21 patients with pulmonary sarcomatoid carcinoma (PSC). The results showed that first-line immunotherapy has promising therapeutic potential in the treatment of PSC, and no serious adverse events were noted. However, further research is needed to confirm these findings.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Nieves Martinez-Lago, Soledad Cameselle Garcia, Beatriz Alonso de Castro, Martin Gomez-Randulfe Rodriguez, Marta Carmona Campos, Paula Gonzalez Villarroel, Mercedes Salgado Fernandez, Juan C. De la Camara Gomez, Carlos Romero Reinoso, Antia Cousillas Castineiras, Jose Carlos Mendez Mendez, Yolanda Vidal Insua, Ana Fernandez-Montes
Summary: The study demonstrates the efficacy of FA in elderly patients, with a need for careful consideration of side effects and dose adjustments in those over 75 years old. It also highlights the predictive value of hypertension for treatment efficacy.
Article
Multidisciplinary Sciences
Sang-A Kim, Hyejoo Park, Kui-Jin Kim, Ji-Won Kim, Ji Hea Sung, Milang Nam, Ju Hyun Lee, Eun Hee Jung, Koung Jin Suh, Ji Yun Lee, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee
Summary: High baseline plasma AREG levels in CRC patients are associated with shorter PFS with cetuximab treatment, but not with PFS or overall survival after chemotherapy failure. AREG may decrease the anti-proliferative effect of cetuximab, but loses this effect after acquiring resistance. Plasma AREG could potentially serve as a biomarker for predicting clinical outcomes with cetuximab-based chemotherapy.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Manish A. Shah, Gyorgy Bodoky, Alexander Starodub, David Cunningham, Desmond Yip, Zev A. Wainberg, Johanna Bendell, Dung Thai, Joyce He, Pankaj Bhargava, Jaffer A. Ajani
Summary: In patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma, the addition of ADX to mFOLFOX6 did not improve overall survival.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Hochster
Summary: The combination of Veliparib and mFOLFIRI did not show improved survival in patients with metastatic pancreatic cancer, while FOLFIRI may be a promising option for pancreatic cancers with HR-DDR defects that warrant further research.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Keisho Chin, Daisuke Takahari, Ryohei Kawabata, Hisashi Hosaka, S. O. Saitou, Takeshi Shiraishi, Hiroshi Yabusaki, Masahiro Goto, Masato Nakamura, Hiroshi Imamura, Yoshiaki Shindo, Fumio Nagashima, Wataru Ichikawa, Takashi Saotome, Wataru Yamamoto, Naoki Ishizuka, Kensei Yamaguchi
Summary: This study suggests that the use of CapeOX regimen as first-line therapy for elderly patients with advanced gastric cancer may lead to adverse reactions, requiring dose reduction or treatment delay to adapt.
ANTICANCER RESEARCH
(2022)
Article
Surgery
Shuo-meng Xiao, Hong-li Ma, Rui Xu, Chao Yang, Zhi Ding
Summary: The study demonstrates that the ERAS protocol can be safely used in elderly gastric cancer patients undergoing gastrectomy, leading to a shorter postoperative hospital stay. There were no significant differences in terms of postoperative complications and hospitalization expenses compared to the conventional group.
ASIAN JOURNAL OF SURGERY
(2022)
Article
Oncology
Elisa Giommoni, Evaristo Maiello, Vanja Vaccaro, Ermanno Rondini, Caterina Vivaldi, Giampaolo Tortora, Laura Toppo, Guido Giordano, Tiziana Pia Latiano, Cinzia Lamperini, Serena Pillozzi, Luca Boni, Lorenzo Antonuzzo, Francesco Di Costanz
Summary: The study evaluated the efficacy of Nab-FOLFIRI and Nab-FOLFOX as first-line chemotherapy for metastatic pancreatic cancer patients, showing high overall response rates and clinical benefit rates, as well as promising 1-year survival rates.
Article
Clinical Neurology
Pia De Stefano, Sira Maria Baumann, Saskia Semmlack, Stephan Ruegg, Stephan Marsch, Margitta Seeck, Raoul Sutter
Summary: The study found that early induction of artificial coma after unsuccessful first-line treatment for SE is more common in younger patients with convulsions and more severe SE. Compared to patients with treatment escalation according to guidelines, this aggressive treatment was not associated with increased complications, but resulted in shorter SE duration, ICU, and hospital stays.
Article
Gastroenterology & Hepatology
Camille Evrard, Christophe Louvet, Farid E. L. Hajbi, Frederic D. Fiore, Karine L. E. Malicot, Thomas Aparicio, Olivier Bouche, Pierre Laurent-Puig, Frederic Bibeau, Thierry Lecomte, Astrid Lievre, Rosine Guimbaud, Stefano Kim, Aziz Zaanan, Harry Sokol, Benoist Chibaudel, Jerome Desrame, Sabrina Pierre, Daniel Gonzalez, Come Lepage, David Tougeron
Summary: The poor overall survival of patients with gastric or gastro-oesophageal junction adenocarcinomas has prompted research into first-line and second-line chemotherapy regimens, as well as the combination of immune checkpoint inhibitors with chemotherapy. Results have been mixed, highlighting the ongoing challenge in treating these types of tumors.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Oncology
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, Carlos Gomez-Roca, Jean-Philippe Metges, Antoine Adenis, Simon Pernot, Carine Bellera, Michele Kind, Celine Auzanneau, Francois Le Loarer, Isabelle Soubeyran, Alban Bessede, Antoine Italiano
Summary: This study demonstrated that the combination of Regorafenib + avelumab has a synergistic effect in a subset of colorectal cancer patients, mobilizing antitumor immunity. Additionally, computational pathology through quantification of immune cell infiltration may improve patient selection for further studies investigating this approach.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Robbert S. Puijk, Muneeb Ahmerh, S. Nahunz Goldberg, Margin K. Meijerink
Summary: This article proposes standardized definitions for oncologic outcome measures, aiming to uniformly document, analyze, and report outcomes to improve reproducibility, allow for accurate comparisons, and avoid misinterpretations in the field of interventional oncology research. The consensus document was developed by an international panel of experts, focusing on when to assess outcomes, definitions of starting and ending time, survival time, and time-to-event end points.
Article
Oncology
Melanie Dos Santos, Idlir Licaj, Carine Bellera, Laurent Cany, Giulia Binarelli, Pierre Soubeyran, Florence Joly
Summary: Chemotherapy-related cognitive impairment is common in elderly cancer patients, with baseline cognitive impairment and malnutrition being identified as independent predictive factors for cognitive decline during treatment. Early detection and management of these risk factors could help improve outcomes in this vulnerable population.
Article
Oncology
Petronella A. L. (Nelleke) Seghers, Jolina A. Kregting, Lieke H. van Huis-Tanja, Pierre Soubeyran, Shane O'Hanlon, Siri Rostoft, Marije E. Hamaker, Johanneke E. A. Portielje
Summary: For older patients with cancer, maintaining cognition and independence, staying in one's own home, and maintaining contact with family and community appear to be the most important aspects of quality of life. Physical functioning, social functioning, physical health, and cognition are important components in quality of life.
Review
Oncology
Petronella A. L. (Nelleke) Seghers, Anke Wiersma, Suzanne Festen, Mariken E. Stegmann, Pierre Soubeyran, Siri Rostoft, Shane O'Hanlon, Johanneke E. A. Portielje, Marije E. Hamaker
Summary: It is important for physicians to understand the treatment outcomes that older patients with cancer prioritize. A systematic review was conducted to identify these outcomes, and the results showed that quality of life, overall survival, progression- and disease-free survival, and severe and persistent side effects of treatment are the highest priority for older patients with cancer.
Article
Oncology
Nadia Oubaya, Pierre Soubeyran, Nicoleta Reinald, Marianne Fonck, Mylene Allain, Sonia Zebachi, Damien Heitz, Marie Laurent, Cecile Delattre, Philippe Caillet, Jerome Dauba, Sylvie Bastuji-Garin, Gilles Albrand, Michael Bringuier, Muriel Rainfray, Etienne Brain, Thomas Grellety, Elena Paillaud, Simone Mathoulin-Pelissier, Carine Bellera, Florence Canoui-Poitrine
Summary: The prognostic assessment of older cancer patients is complicated by their heterogeneity, and routine inflammatory biomarkers play an important role in prognosis assessment. The study found that GPS and CRP/albumin ratio were independently associated with mortality and increased discriminative power. Routine inflammatory biomarkers in older cancer patients add prognostic value to clinical factors.
Article
Cell Biology
Faten Merhi, Karla Alvarez-Valadez, Jenifer Trepiana, Claire Lescoat, Alexis Groppi, Jean-William Dupuy, Pierre Soubeyran, Guido Kroemer, Pierre Vacher, Mojgan Djavaheri-Mergny
Summary: ATRA promotes calcium entry through SOC channels into APL cells, activating CAMKK2 and AMPK to link Ca2+ signaling to autophagy. Pharmacological inhibition of SOC channels and CAMKK2 enhances ATRA-induced cell differentiation and death.
Review
Oncology
Florent Guerville, Isabelle Bourdel-Marchasson, Julie Dechanet-Merville, Isabelle Pellegrin, Pierre Soubeyran, Victor Appay, Mael Lemoine
Summary: Aging is associated with chronic low-grade inflammation, cancer incidence and mortality. However, specific inflammatory pathways explaining cancer incidence or mortality during aging still lack convincing evidence.
Article
Oncology
Marion Barrault-Couchouron, Noemi Micheli, Pierre Soubeyran
Summary: The study evaluated the collaboration between oncologists and geriatricians, identifying key aspects such as shared time, routines, medical decision criteria, and perceptions of elderly patient needs that may influence their collaboration. The findings suggest the need to optimize oncogeriatric care and improve collaboration between the two disciplines.
Article
Oncology
Adolfo Gonzalez Serrano, Marie Laurent, Thomas Barnay, Claudia Martinez-Tapia, Etienne Audureau, Pascaline Boudou-Rouquette, Thomas Aparicio, Florence Rollot-Trad, Pierre Soubeyran, Carine Bellera, Philippe Caillet, Elena Paillaud, Florence Canoui-Poitrine
Summary: Frailty screening can help identify unfit patients in need of geriatric assessment and avoid unnecessary assessment in fit patients. However, the accuracy of screening tests and their clinical benefits have not been confirmed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Elena Paillaud, Marije E. Hamaker, Pierre Soubeyran
Article
Oncology
James Miles, Isabelle Soubeyran, Florence Marliot, Nicolas Pangon, Antoine Italiano, Carine Bellera, Stephen G. Ward, Franck Pages, Jean Palussiere, Banafshe Larijani
Summary: Radiofrequency ablation (RFA) for the treatment of pulmonary metastases may stimulate an immune response in the remaining tumors. Immune checkpoint interactions may limit this response. A imaging platform that quantifies checkpoint interactions can enhance treatment response in metastatic patients.
Article
Oncology
Serge Evrard, Carine Bellera, Gregoire Desolneux, Coralie Cantarel, Emilie Toulza, Jean-Luc Faucheron, Michel Rivoire, Aurelien Dupre, Jean-Yves Mabrut, Laurent Bresler, Frederic Marchal, Damien Bouriez, Eric Rullier
Summary: The two multicenter single-arm phase II trials showed that delayed colo-anal anastomosis (DCAA) has low rates of anastomotic leakage requiring a diverting ileostomy and acceptable long-term functional results.
Article
Oncology
Paul Sargos, Eberhard Stoeckle, Anne Ducassou, Antoine Giraud, Augustin Mervoyer, Antoine Italiano, Sabrina Albert, Gwenael Ferron, Carine Bellera, Guy Kantor
Summary: This study evaluated the efficacy and feasibility of high-dose intensity-modulated radiotherapy in patients with retroperitoneal liposarcomas. The results showed significant toxicity and rates of second cancers associated with this treatment regimen. Therefore, the optimal indication of radiotherapy for patients with retroperitoneal liposarcomas still needs to be determined.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Gastroenterology & Hepatology
Leonard Depotte, Juliette Palle, Cosimo Rasola, Chloe Broudin, Vlad-Adrian Afrasanie, Antoine Mariani, Aziz Zaanan
Summary: Advanced gastric adenocarcinoma is a disease with poor prognosis. In recent years, new drugs, such as trastuzumab for HER2-positive tumors, ramucirumab alone or in combination with paclitaxel, and trifluridine-tipiracil, have improved patient survival. Other drugs, including monoclonal antibodies and targeted therapies, are also being evaluated.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2024)